Benchmark Reiterates Buy Rating on CNK

Benchmark analyst Mike Hickey has reiterated his buy rating on CNK, setting a price target of $37. This decision came on June 17, 2026, as CNK shares were trading at $33.02. Hickey's outlook reflects continued confidence in CNK's performance potential.

Other Institutional Activity in CNK

Several major institutional investors have adjusted their positions in CNK. BlackRock, Inc. increased its holdings by 580,341 shares, bringing its total to 15,805,826 shares valued at about $450.8 million. Orbis Allan Gray Ltd held steady with 15,057,911 shares worth $429.5 million. Wellington Management Group LLP reduced its stake by 781,575 shares, now holding 8,755,325 shares valued at approximately $249.7 million. Meanwhile, Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both initiated new positions with 6,061,102 and 4,663,399 shares, respectively.

Cinemark Holdings, Inc. Stock Down 0.3%

Shares of CNK are trading at $33.02. The stock's recent activity includes significant insider sales and institutional adjustments. These market movements suggest varying levels of confidence and strategy among key stakeholders.

Insider Buying and Selling at Cinemark Holdings, Inc.

Recent insider transactions at CNK include several sales. On June 11, 2026, Valmir Fernandes, President of Cinemark International, sold 30,000 shares at $33.50 each. Wanda Marie Gierhart, Chief Marketing & Content Officer, sold a total of 49,681 shares between June 8 and June 10 at prices ranging from $31.50 to $33.00. Caren Bedard, the SVP-Global Controller, sold 8,000 shares at $30.23 on June 4.

Analysts Set New Price Targets

On June 17, 2026, Benchmark maintained its buy rating on CNK with a $37 price target. Other analysts have also weighed in recently. B. Riley Securities and Morgan Stanley both maintained hold ratings with $36 targets on June 11 and June 9, respectively. JP Morgan, Macquarie, and Barrington Research all maintained buy ratings with $36 targets on May 4.

Bottom Line

Benchmark's reiteration of a buy rating and a $37 price target underscores its positive outlook on CNK. While insider sales and varied institutional activity may suggest differing market perspectives, Benchmark's stance highlights confidence in CNK's future prospects. Investors should note that these analyses and transactions reflect past data and may not indicate current positions or future performance.